Universal-Beteiligungs- und Servicegesellschaft
SYRE icon

Universal-Beteiligungs- und Servicegesellschaft’s Spyre Therapeutics SYRE Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
172,923
+2,542
+1% +$185K 0.02% 494
2026
Q1 		$8.59M Sell
170,381
-830
-0.5% -$31.3K 0.01% 664
2025
Q4 		$5.61M Buy
171,211
+60,755
+55% +$1.59M 0.01% 838
2025
Q3 		$1.85M Buy
110,456
+1,172
+1% +$19.1K ﹤0.01% 1329
2025
Q2 		$1.64M Sell
109,284
-11,037
-9% -$163K ﹤0.01% 1323
2025
Q1 		$1.94M Sell
120,321
-1,832
-1% -$38.1K ﹤0.01% 1212
2024
Q4 		$2.84M Buy
+122,153
New +$3.58M 0.01% 836

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's SYRE Position: Q2 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft increased its Spyre Therapeutics (SYRE) stake by 1.5% in Q2 2026, buying an estimated $185K and bringing the position to 172,923 shares worth $15.4M. The position accounts for 0.02% of the portfolio, ranked #494.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Universal-Beteiligungs- und Servicegesellschaft held 172,923 shares of Spyre Therapeutics worth $15.4M as of Q2 2026.
  • Universal-Beteiligungs- und Servicegesellschaft bought 2,542 Spyre Therapeutics shares in Q2 2026, an estimated $185K.
  • Spyre Therapeutics made up 0.02% of Universal-Beteiligungs- und Servicegesellschaft's portfolio in Q2 2026, its #494 holding.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2026, filed 6 Aug 2026.